Indian Journal of Gastroenterology

, Volume 37, Issue 2, pp 127–132 | Cite as

Outcome of transarterial chemoembolization in Egyptian patients with hepatocellular carcinoma and branch portal vein thrombosis

  • H. Abdella
  • M. K. Shaker
  • Iman Fawzy Montasser
  • M. Sobhi
  • H. Aly
  • A. Sayed
  • S. Saleh
  • A. El Dorry
Original Article
  • 94 Downloads

Abstract

Background/Aim

Portal vein tumor thrombosis (PVTT) is a common complication in hepatocellular carcinoma (HCC) and it was considered a relative contraindication for transarterial chemoembolization (TACE) by many centers. This study aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response, and 1-year survival.

Methods

Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT underwent TACE. Follow up was done at 1, 3, 6, and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions and triphasic spiral computed tomography to assess radiological response according to modified response evaluation criteria in solid tumors (mRECIST) criteria, and survival analysis was recorded.

Results

TACE succeeded to achieve disease control in 93.3%, 86.3%, 57.7%, and 44.4% of patients after 1, 3, 6, and 12 months, respectively. Post-TACE liver decompensation occurred in the form of ascites in 30%, jaundice in 10%, and hepatic encephalopathy in 3.3% within 1 month of TACE. One month survival after TACE was 100%, 3 months was 96.6%, 6 months was 86.6%, and 1-year survival was 60%. Mean overall survival of the included patients was 17 months (SE = 1.59).

Conclusion

TACE seems an alternative option for patients with unrespectable HCC with portal vein thrombosis in patients with good liver function tests.

Keywords

Hepatocellular carcinoma Portal vein thrombosis Transarterial chemoembolization 

Notes

Compliance with ethical standards

Conflict of interest

HA, MKS, IFM, MS, HA, AS, SS, and AEl-D declare that they have no conflict of interest.

Ethics statement

The study was approved by the Research and Ethics Committee of Ain Shams University, in accordance with local research governance requirements; the trial was registered with the federal clearing house for randomized trials on the ClinicalTrials.gov (NCT03007212).

References

  1. 1.
    IARC: preventable exposures associated with human cancers. J Natl Cancer Inst 2011; 103:1–14.Google Scholar
  2. 2.
    Llovet J, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599–641.CrossRefGoogle Scholar
  3. 3.
    Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52:762–73.CrossRefPubMedGoogle Scholar
  4. 4.
    Quirk M, Kim Y, Saab S, Wolfgang LE. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462–71.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yu J, Yoon S, Park H, et al. Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat. 2014;46:348–57.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Forner A, Reig M, de Lope C, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lencioni R, Llovet J. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Shaker M, Abdella H, Khalifa M, El Dorry A. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int. 2013;33:1601–6.PubMedGoogle Scholar
  10. 10.
    Song D, Nam S, Bae S, et al. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol. 2015;21:2395–404.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kim K, Kim J, Park I, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806–14.CrossRefPubMedGoogle Scholar
  12. 12.
    Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. ANZ J Surg. 2016;86:816–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258:627–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Jeon S, Park K, Kim Y, et al. Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J Gastroenterol. 2007;50:176–82.PubMedGoogle Scholar
  15. 15.
    Georgiades C, Hong K, D’Angelo M, Geschwind J. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2005;16:1653–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol. 2011;18:413–20.CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2018

Authors and Affiliations

  1. 1.Departments of Tropical Medicine, Faculty of MedicineAin Shams UniversityCairoEgypt
  2. 2.Radiodiagnosis and Intervention RadiologyAin Shams UniversityCairoEgypt
  3. 3.Internal MedicineAin Shams UniversityCairoEgypt

Personalised recommendations